Abpro is a biotechnology company dedicated to developing next-generation antibody therapeutics to improve the lives of patients with severe and life-threatening diseases. Abpro’s antibody discovery and engineering platform, the DiversImmune™ platform, enables the generation of novel antibodies and next-generation antibody therapies. Abpro is leveraging these platforms, both independently and though collaborations with global pharmaceutical companies and research institutions to develop therapeutic antibodies for use in immuno-oncology, ophthalmology, and other disease areas. Abpro is based in Woburn, Massachusetts.